CacoReady Plates Aid Discovery of Novel HDAC Inhibitors for Prostate Cancer
Cutting-edge CacoReady Cell-based Plates with pre-developed Caco-2 cells for in vitro permeability assessment have been a key tool in a
Read moreCutting-edge CacoReady Cell-based Plates with pre-developed Caco-2 cells for in vitro permeability assessment have been a key tool in a
Read moreAbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read moreBoehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read moreStressMarq Biosciences, a market leader and pioneer in the field of fibrilized and oligomeric protein preparations for neurodegenerative disease research,
Read moreIn a groundbreaking development for the vaccine development sector, biotech company Valneva SE announced, that the U.S. Food and Drug
Read moreVANFLYTA® (quizartinib) is now the first FLT3 inhibitor approved in the European Union (EU) specifically for the treatment of patients
Read moreStressMarq Biosciences, a pioneer in the development and commercialization of unique fibrilized and oligomeric protein preparations to propel the study
Read moreA collaboration between StressMarq Biosciences and Gubra has generated a 3D whole-brain light sheet fluorescence imaging model depicting alpha-synuclein pSer129+
Read moreSwiss pharma giant Roche has entered an agreement to purchase Telavant Holdings, a Roivant company, owned by Roivant Sciences Ltd.
Read moreStressMarq manufactures and offers a wide range of products specifically developed to accelerate Parkinson’s disease research. StressMarq’s cutting-edge product range
Read more